SEC Form 4 · accession 0001144204-15-054447
Armata Pharmaceuticals, Inc. · ARMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendy S. Johnson
Officer — See Remarks · Director
Period of report
Sep 8, 2015
Accepted (ET)
Sep 10, 2015 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921114
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.46 | Sep 8, 2015 | A | 49,965 | A | — | Sep 8, 2025 | Common Stock | 49,965 | 49,965 | D |
Explanation of responses
- F1One-half of the shares underlying this option will vest and become exercisable upon AmpliPhi Bioscience Corporation's (the "Company") satisfaction of certain business goals. One-half of the shares underlying this option will vest on an equal monthly basis over the 12 months following July 1, 2015, subject to the Consulting Agreement, dated September 3, 2015, by and between the Company and Wendy S. Johnson, remaining in effect as of the applicable vesting date.
Remarks
Interim Chief Operating Officer